Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PTPRA | P18433 | 1/20 | 0.59 |
| ▸ | PTPRB | P23467 | 1/20 | 0.59 |
| ▸ | PTPRE | P23469 | 1/20 | 0.59 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GFER | P55789 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30517876 | 1.00 | PTPRC (0.59) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL8243668 | 0.88 | RXFP1 (0.45) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL7846188 | 0.86 | PTPN1 (0.64) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL1767849 | 0.85 | KMT2A (0.52) | CA12CA7MEN1KMT2AGFER | |
| SCHEMBL27852761 | 0.85 | MEN1 (0.56) | CA12CA7MEN1KMT2AGFER | |
| SCHEMBL31619048 | 0.85 | KMT2A (0.52) | CA12CA7MEN1KMT2AGFER | |
| SCHEMBL3887267 | 0.84 | PTPRC (0.66) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL18522602 | 0.84 | HPGD (0.46) | PTPRCPTPN2PTPN1PTPRAPTPRB | |
| SCHEMBL29259910 | 0.82 | KDM4E (0.63) | CA12CA7MEN1KMT2ASERPINE1 | |
| SCHEMBL30517815 | 0.82 | POLB (0.53) | MEN1KMT2AKDM4EALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4673442-A1 | PHOTOSWITCHABLE COMPOUNDS AND AFFINITY LIGANDS, AND THEIR USE FOR THE OPTICAL CONTROL OF AFFINITY MATRICES | AFC Innovations GmbH (DE) | 2026-01-07 | — | — | EP | disclosed |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-05-01 | — | — | US | disclosed |
| WO-2024180254-A1 | PHOTOSWITCHABLE COMPOUNDS AND AFFINITY LIGANDS, AND THEIR USE FOR THE OPTICAL CONTROL OF AFFINITY MATRICES | AFC INNOVATIONS GMBH (DE) | 2024-09-06 | — | — | WO | disclosed |
| CN-116693515-A | GST protein inhibitor, preparation method thereof, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-09-05 | — | — | CN | disclosed |
| WO-2023154197-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | HEPANOVA, INC. | 2021-11-04 | — | — | US | disclosed |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | HEPANOVA, INC. (US) | 2021-05-11 | — | — | US | disclosed |
| US-7572813-B2 | Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-08-11 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT | 2006-06-22 | — | — | US | disclosed |
| US-7045521-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT (US) | 2004-06-10 | — | — | US | disclosed |
| US-6706712-B2 | RHEUMATIC DISEASES, MULTIPLE SCLEROSIS, ASTHMA, ANTICHOLESTEROL AGENTS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-16 | — | — | US | disclosed |
| EP-1343751-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-01-02 | — | — | US | disclosed |
| WO-2002060859-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | PTPRC 3729/4885PTPN2 3101/4885PTPN1 3108/4885 |
| US-20040110736-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | PTPRC 2102/4885PTPN2 3285/4885PTPN1 2285/4885 |
| US-20030004151-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | PTPRC 2102/4885PTPN2 3285/4885PTPN1 2285/4885 |
| US-20250134907-A1 | FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF | RXFP3, RXFP4, RXFP2 | PTPRC 4244/4885PTPN2 3151/4885PTPN1 3956/4885 |
| US-20060135502-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | PTPRC 1733/4885PTPN2 3066/4885PTPN1 2278/4885 |
| US-11000491-B2 | Amino-aryl-benzamide compounds and methods of use thereof | AADAC, GOT2, ABAT | PTPRC 4394/4885PTPN2 3611/4885PTPN1 3971/4885 |
| US-20210338610-A1 | AMINO-ARYL-BENZAMIDE COMPOUNDS AND METHODS OF USE THEREOF | AADAC, GOT2, ABAT | PTPRC 4394/4885PTPN2 3611/4885PTPN1 3971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.